Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection

[1]  F. Kostolanský,et al.  Two distinct regions of HA2 glycopolypeptide of influenza virus hemagglutinin elicit cross-protective immunity against influenza. , 2012, Acta virologica.

[2]  Martin H. Koldijk,et al.  A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses , 2011, Science.

[3]  Gira Bhabha,et al.  Antibody Recognition of a Highly Conserved Influenza Virus Epitope , 2009, Science.

[4]  I. Wilson,et al.  A Virus-Like Particle That Elicits Cross-Reactive Antibodies to the Conserved Stem of Influenza Virus Hemagglutinin , 2012, Journal of Virology.

[5]  Samson S. Y. Wong,et al.  Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus , 2008, Proceedings of the National Academy of Sciences.

[6]  P. Šebo,et al.  Heterosubtypic protection against influenza A induced by adenylate cyclase toxoids delivering conserved HA2 subunit of hemagglutinin. , 2013, Antiviral research.

[7]  P. Palese,et al.  Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo , 2014, Nature Medicine.

[8]  Kwok-Hung Chan,et al.  Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. , 2012, Vaccine.

[9]  D. Burke,et al.  Limited airborne transmission of influenza A/H7N9 virus between ferrets , 2013, Nature.

[10]  K. To,et al.  Clinical, virological, and histopathological manifestations of fatal human infections by avian influenza A(H7N9) virus. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  K. To,et al.  Immunogenicity of intradermal trivalent influenza vaccine with topical imiquimod: a double blind randomized controlled trial. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  John Steel,et al.  Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain , 2010, mBio.

[13]  K. To,et al.  Unique reassortant of influenza A(H7N9) virus associated with severe disease emerging in Hong Kong , 2014, Journal of Infection.

[14]  K. To,et al.  High Incidence of Severe Influenza among Individuals over 50 Years of Age , 2011, Clinical and Vaccine Immunology.

[15]  S. Akira,et al.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.

[16]  K. To,et al.  Mice A ( H 1 N 1 ) pdm 09 Virus Infection in BALB / c Responses against Influenza Expedites and Augments Humoral Immune Combination with Influenza Vaccine Toll-Like Receptor 7 Agonist Imiquimod in , 2014 .

[17]  P. Woo,et al.  SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus , 2005, Vaccine.

[18]  K. To,et al.  Differences in Antibody Responses of Individuals with Natural Infection and Those Vaccinated against Pandemic H1N1 2009 Influenza , 2011, Clinical and Vaccine Immunology.

[19]  F. Kostolanský,et al.  Antibodies induced by the HA2 glycopolypeptide of influenza virus haemagglutinin improve recovery from influenza A virus infection. , 2008, The Journal of general virology.

[20]  K. To,et al.  Analytical Sensitivity of Seven Point-of-Care Influenza Virus Detection Tests and Two Molecular Tests for Detection of Avian Origin H7N9 and Swine Origin H3N2 Variant Influenza A Viruses , 2013, Journal of Clinical Microbiology.

[21]  J. Chan,et al.  The emergence of influenza A H7N9 in human beings 16 years after influenza A H5N1: a tale of two cities , 2013, The Lancet Infectious Diseases.

[22]  K. Yuen,et al.  Influenza vaccination: options and issues. , 2005, Hong Kong medical journal = Xianggang yi xue za zhi.

[23]  Guohua Deng,et al.  H7N9 Influenza Viruses Are Transmissible in Ferrets by Respiratory Droplet , 2013, Science.

[24]  R. Varadarajan,et al.  Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection , 2014, Proceedings of the National Academy of Sciences.

[25]  Jie Dong,et al.  Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus. , 2018 .

[26]  K. To,et al.  Avian-origin influenza A(H7N9) infection in influenza A(H7N9)-affected areas of China: a serological study. , 2014, The Journal of infectious diseases.

[27]  Herman Tse,et al.  Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests , 2013, Journal of Infection.

[28]  M. Fenton,et al.  Immunobiology of influenza vaccines. , 2013, Chest.

[29]  Herman Tse,et al.  Two Years after Pandemic Influenza A/2009/H1N1: What Have We Learned? , 2012, Clinical Microbiology Reviews.

[30]  Jian He,et al.  Clinical findings in 111 cases of influenza A (H7N9) virus infection. , 2013, The New England journal of medicine.

[31]  N. Heaton,et al.  Hemagglutinin Stalk-Based Universal Vaccine Constructs Protect against Group 2 Influenza A Viruses , 2013, Journal of Virology.

[32]  P. Palese,et al.  A Pan-H1 Anti-Hemagglutinin Monoclonal Antibody with Potent Broad-Spectrum Efficacy In Vivo , 2012, Journal of Virology.

[33]  A. Vincent,et al.  Vaccine-Induced Anti-HA2 Antibodies Promote Virus Fusion and Enhance Influenza Virus Respiratory Disease , 2013, Science Translational Medicine.

[34]  N. Khardori.  Universal Vaccine Based on Ectodomain of Matrix Protein 2 of Influenza A: Fc Receptors and Alveolar Macrophages Mediate Protection , 2011 .

[35]  K. To,et al.  High Titer and Avidity of Nonneutralizing Antibodies against Influenza Vaccine Antigen Are Associated with Severe Influenza , 2012, Clinical and Vaccine Immunology.

[36]  A. García-Sastre,et al.  Protection of Mice against Lethal Challenge with 2009 H1N1 Influenza A Virus by 1918-Like and Classical Swine H1N1 Based Vaccines , 2010, PLoS pathogens.

[37]  K. To,et al.  Leptin mediates the pathogenesis of severe 2009 pandemic influenza A(H1N1) infection associated with cytokine dysregulation in mice with diet-induced obesity. , 2013, The Journal of infectious diseases.

[38]  Walter Fiers,et al.  A universal influenza A vaccine based on the extracellular domain of the M2 protein , 1999, Nature Medicine.

[39]  R. Varadarajan,et al.  Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge , 2010, Proceedings of the National Academy of Sciences.

[40]  Wenjun Song,et al.  Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome , 2013, The Lancet.